Omeprazole | Proficient Rx Lp while Breastfeeding

Nutrients from the food that you eat passes to your breast milk. Its good idea to take healthy diet while breastfeeding. You may need to consume more calories per day to support healthy body system. Some time it gets necessary take medicine while you are breastfeeding and as other food items passes into breast milk, medicine passes as well hence it becomes obvious to understand its effects while breastfeeding. We have analyzed many medications and in this sheet we will present some fact and known information associated with Omeprazole | Proficient Rx Lp while breast-feeding.

Omeprazole delayed-release capsule USP is a proton pump inhibitor indicated for: • Treatment in adults of duodenal ulcer (1.1) and gastric ulcer (1.2) • Treatment in adults and children of gastroesophageal reflux disease (GERD) (1.3) and maintenance of healing of erosive esophagitis (1.4) • Pathologic Hypersecretory Conditions (1.5) The safety and effectiveness of omeprazole in pediatric patients <1 year of age have not been established. (8.4) 1.1 Duodenal Ulcer (adults) Omeprazole delayed-release capsules USP are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. Omeprazole delayed-release capsules USP in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Omeprazole delayed-release capsules USP in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies (14.1)and Dosage and Administration (2)]. Among patients who fail therapy, omeprazole delayed-release capsules USP with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted. [see Microbiology section (12.4)], and the clarithromycin package insert, Microbiology section. 1.2 Gastric Ulcer (adults) Omeprazole delayed-release capsules USP are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. [SeeClinical Studies (14.2)] 1.3 Treatment of Gastroesophageal Reflux Disease (GERD) (adults and pediatric patients) Symptomatic GERD Omeprazole delayed-release capsules USP are indicated for the treatment of heartburn and other symptoms associated with GERD in pediatric patients and adults for up to 4 weeks. Erosive Esophagitis Omeprazole delayed-release capsules USP are indicated for the short-term treatment (4 to 8 weeks) of erosive esophagitis that has been diagnosed by endoscopy in pediatric patients and adults. [See Clinical Studies (14.4)] The efficacy of omeprazole delayed-release capsules USP used for longer than 8 weeks in these patients has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of erosive esophagitis or GERD symptoms (eg, heartburn), additional 4 to 8 week courses of omeprazole may be considered. 1.4 Maintenance of Healing of Erosive Esophagitis (adults and pediatric patients) Omeprazole delayed-release capsules USP are indicated to maintain healing of erosive esophagitis in pediatric patients and adults. Controlled studies do not extend beyond 12 months. [See Clinical Studies (14.4)]. 1.5 Pathological Hypersecretory Conditions (adults) Omeprazole delayed-release capsules USP are indicated for the long-term treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults.

Statement of Manufacturer/Labeler about breastfeeding usage
8.3 Nursing Mothers Omeprazole is present in human milk. Omeprazole concentrations were measured in breast milk of a woman following oral administration of 20 mg. The peak concentration of omeprazole in breast milk was less than 7% of the peak serum concentration. This concentration would correspond to 0.004 mg of omeprazole in 200 mL of milk. Caution should be exercised when omeprazole is administered to a nursing woman.